ST-100 (Vezocolmitide)
Dry Eye Disease
Phase 3Active
Key Facts
About Stuart Therapeutics
Stuart Therapeutics is a private, clinical-stage biotech pioneering a novel approach to treating chronic ocular diseases by targeting helical collagen in the extracellular matrix. Its proprietary PolyCol platform technology consists of synthetic peptides designed to bind and repair damaged collagen, a previously 'undruggable' target involved in inflammation and tissue structure. The company's most advanced asset, ST-100 (Vezocolmitide), has reported Phase III results for Dry Eye Disease, and it has secured a key partnership with Glaukos Corporation. With a pipeline focused on major unmet needs in ophthalmology, Stuart aims to develop disease-modifying therapies that go beyond symptom management.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Elate Ocular® | Cambium Bio | Phase 3 |
| OT-301 | Ocumension Therapeutics | Phase 2 |
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Care Portfolio | YD Bio | Commercial |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |
| MediPrint Lens (Dry Eye) | MediPrint Ophthalmics | Pre-clinical/Research |
| Tivanisiran | Sylentis | Phase 2/3 |
| A197 | Aramis Biosciences | Phase 2 |
| KM102 | Theratome Bio | Pre-clinical |
| iTEAR®100 Commercialization | Olympic Ophthalmics | Commercial |
| HydraD | EyeD Pharma | Pre-Clinical |
| BRM421 | BRIM Biotechnology | Phase 3 |